Skip to main content

Day: October 7, 2025

Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

Recent Issuance of U.S. Patents Covering ImmCelz™ — Supercharged Regulatory T Cell Programs in Heart Failure and Type 1 Diabetes Reinforce Creative Medical’s Similar Research Focus PHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today congratulated Mary E. Brunkow, Ph.D., Fred Ramsdell, Ph.D., and Shimon Sakaguchi, M.D., Ph.D. on being awarded the 2025 Nobel Prize in Physiology or Medicine for foundational discoveries in peripheral immune tolerance and the biology of regulatory T cells (Tregs). Their work—including the identification of Tregs and the central role of FOXP3—reshaped modern immunology and catalyzed new treatment strategies across autoimmunity,...

Continue reading

Jet.AI Announces Successful Closing of AI Infrastructure Acquisition Corp., Adding Approximately $20 Million in Book Equity from Its Ownership Stake

LAS VEGAS, Oct. 07, 2025 (GLOBE NEWSWIRE) — Jet.AI (the “Company”) (Nasdaq: JTAI), a provider of high-performance GPU infrastructure and AI cloud services, announced that on October 3, 2025, AI Infrastructure Acquisition Corp. (NYSE: AIIAU), a special purpose acquisition company (SPAC), has successfully closed its initial public offering of 12,000,000 units at an offering price of $10.00 per unit. The offering was significantly oversubscribed and upsized from an initial 10,000,000 units because of strong demand. As previously disclosed, Jet.AI made a capital contribution to AIIA Sponsor Ltd. (the “Sponsor”), as the sponsor of AI Infrastructure Acquisition Corp., and holds a 49.5% ownership interest in the Sponsor. Based on the initial public offering price, Jet.AI’s ownership stake is expected to provide an initial...

Continue reading

AiRWA Inc. Announces Receipt of $30 Million of Solana Tokens into AiRWA Exchange, as well as Successful Test Runs Settling Trades of Tokenized U.S. Equities

Smyrna, Delaware, Oct. 07, 2025 (GLOBE NEWSWIRE) — AiRWA Inc. (Nasdaq: YYAI) (“AiRWA”) announces that it has received an investment of approximately $30 million of Solana tokens. These tokens will not only bolster the financial foundation of AiRWA Exchange but also help drive the platform’s strategic focus on integrating Solana as a core asset for its major trading pairs. In addition, AiRWA Exchange has successfully completed its test runs for settling trades of tokenized U.S. equities. This milestone positions AiRWA to offer users the ability to trade digital representations of U.S. stocks with the same simplicity and speed as cryptocurrencies, enabling seamless transactions on the blockchain. While some traditional brokerage firms, such as Robinhood, have begun offering tokenized stocks to their customers, AiRWA Exchange is taking...

Continue reading

24/7 Market News- Kraig Labs Unlocks Spider Silk at Scale, Solving a Centuries-Old Problem of Nature’s Strongest Fiber

DENVER, Oct. 07, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed global leader in the development and commercialization of spider silk, achieved a milestone in biotechnology: the successful mass production of spider silk using silkworms, solving a challenge that has eluded scientists and engineers for decades. For years, researchers have known that spider silk is one of the toughest fibers known to man, but it has many other highly beneficial properties, like biocompatibility and biodegradability; a near-miraculous combination of properties. Yet despite decades of interest from the military, biomedical researchers, and textile designers, spider silk remained mostly...

Continue reading

Aptean Expands Dealer Management Platform and Nordic Footprint Through Acquisition of JMA

Cloud ERP solution purpose-built for agricultural and construction machinery industry RANDERS, Denmark and ALPHARETTA, Ga., Oct. 07, 2025 (GLOBE NEWSWIRE) — Aptean Inc., a global front-runner of AI-driven ERP solutions, is pleased to announce the acquisition of JMA A/S (“JMA”), a leading provider of dealer management system solutions for the heavy equipment, agricultural and construction machinery vertical in the Nordic market, headquartered in Randers, Denmark. The acquisition of JMA further increases Aptean’s Nordic footprint, while also bolstering the capabilities of Aptean’s dealer management offerings, purpose-built for the agricultural and construction machinery sector. Founded in 1990, JMA provides a mission-critical dealer management solution (“DSM”) which is designed to connect and digitize every part of the agricultural...

Continue reading

PacBio Expands Partnership with seqWell to Bring Scalable Long Read Sample Prep to More Labs

Highly scalable, cost-effective LongPlex™ kit delivers streamlined tagmentation and multiplexing for low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing MENLO PARK, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) — PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced an expanded partnership with seqWell, a global provider of genomic library and multiplexing workflow solutions. Under the new agreement, PacBio will distribute seqWell’s LongPlex™ Multiplexing Kit, a scalable, easy-to-use sample preparation solution designed for use with PacBio HiFi sequencing and optimized for efficient transposase-based DNA fragmentation and multiplexing. LongPlex removes sample prep bottlenecks, enabling researchers to produce high-quality libraries quickly,...

Continue reading

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is expected to diversify and accelerate MannKind’s double-digit revenue growth, driven by FUROSCIX® (furosemide injection), an innovative therapy for edema due to chronic heart failure and chronic kidney disease. The transaction will strengthen MannKind’s commercial and medical capabilities by integrating scPharmaceuticals’ experienced team into its existing infrastructure. MannKind is positioned as a diversified, growth-focused biopharmaceutical company with its commercial assets—Afrezza®, FUROSCIX® and V-Go®—along with Tyvaso DPI®-related revenues, contributing to an annualized run rate of over $370...

Continue reading

Plug Power Names Jose Luis Crespo as Incoming CEO to Succeed Long-Term Leader Andy Marsh

CEO transition to take effect in March 2026 SLINGERLANDS, N.Y., Oct. 07, 2025 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in end-to-end hydrogen solutions for the hydrogen economy, today announces the appointment of Jose Luis Crespo as President, effective as of October 10, 2025, and as its new Chief Executive Officer, to be effective as of the date the company files its Annual Report on Form 10-K for the year ended December 31, 2025, expected March 2026. Mr. Crespo will succeed Mr. Andy Marsh as CEO. Mr. Marsh will continue to serve as CEO during the transition period and has been appointed Executive Chair of the Board, a position he will retain following March 2, 2026. In conjunction, George McNamee has been named Lead Director. Both Board appointments are effective October 10, 2025. Together, these leadership...

Continue reading

Applied Materials Unveils Next-Gen Chipmaking Products to Supercharge AI Performance

Kinex™ Bonding SystemThe Kinex™ Bonding system is the industry’s first integrated die-to-wafer hybrid bonder. It enables production of higher performance, lower power advanced logic and memory chips by integrating all the critical hybrid bonding process steps into one system.Centura™ Xtera™ Epi SystemThe Xtera™ Epi system enables higher performance Gate-All-Around transistors at 2nm and beyond by depositing void-free, uniform epitaxial layers.PROVision™ 10 eBeam Metrology SystemThe PROVision™ 10 eBeam metrology system improves yield of complex 3D chips by providing sub-nanometer resolution, fast throughput and deep imaging.Kinex™ is the industry’s first integrated die-to-wafer hybrid bonding system; enables production of higher performance, lower power...

Continue reading

AirJoule Technologies and the U.S. Army Engineer Research and Development Center to Collaborate on Atmospheric Water Generation Using Waste Heat

Research collaboration aims to develop a more resilient and fuel-efficient water supply for future military applications RONAN, Mont., Oct. 07, 2025 (GLOBE NEWSWIRE) — AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AirJoule Technologies” or the “Company”), a leading technology platform that unleashes the power of water from air, today announced a three-year Cooperative Research and Development Agreement (“CRADA”) with the U.S. Army Engineer Research and Development Center (“ERDC”). The collaboration between ERDC’s operational water research team and AirJoule Technologies will leverage the combination of ERDC’s tactical generator waste heat recovery systems and the state-of-the-art AirJoule™ platform for extracting moisture from ambient air. The goal of the collaboration is to develop more resilient supply of potable...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.